Centiva Capital LP lifted its position in BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating) by 3.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,250 shares of the company's stock after buying an additional 3,250 shares during the period. Centiva Capital LP owned approximately 0.35% of BioPlus Acquisition worth $1,038,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of BIOS. Highbridge Capital Management LLC purchased a new position in shares of BioPlus Acquisition in the 1st quarter worth $11,719,000. Goldman Sachs Group Inc. purchased a new position in BioPlus Acquisition during the first quarter valued at $8,152,000. Polar Asset Management Partners Inc. purchased a new position in BioPlus Acquisition during the first quarter valued at $7,410,000. MMCAP International Inc. SPC purchased a new position in BioPlus Acquisition during the first quarter valued at $6,422,000. Finally, Starboard Value LP purchased a new position in BioPlus Acquisition during the first quarter valued at $6,098,000. 65.67% of the stock is currently owned by hedge funds and other institutional investors.

BioPlus Acquisition Trading Up 0.1 %

NASDAQ BIOS opened at $10.20 on Monday. The business's fifty day moving average is $10.13 and its 200 day moving average is $10.03. BioPlus Acquisition Corp. has a fifty-two week low of $9.78 and a fifty-two week high of $10.20.

About BioPlus Acquisition

BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.

Further Reading

• Get a free copy of the StockNews.com research report on BioPlus Acquisition (BIOS)
• Dave & Buster's Proves Experiential Dining Demand is Strong
• Does Lululemon's 12% Drop Signal Bad News For Clothing Retailers?
• MarketBeat: Week in Review 12/05 – 12/09
• There Is Fundamental Value In Broadcom, And It Yields 3.35%
• Costco vs Amazon: an end of the year showdown

Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating).

Receive News & Ratings for BioPlus Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPlus Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.